Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study
Atherosclerosis Apr 11, 2020
Casula M, Olmastroni E, Galimberti F, et al. - By performing a retrospective cohort analysis, researchers assessed how bisphosphonates can influence hospitalizations for atherosclerotic cardiovascular (CV) events. Participants were people aged > 40 years, incident users of bisphosphonates. Depending on cumulative doses (proportion of days covered, PDC), exposure to bisphosphonates was defined. Experts categorized treatment's adherence as low (PDC ≤ 40%), intermediate (PDC 41%–80%), or high (PDC > 80%). Findings revealed a better CV outcome in relation to strict adherence to bisphosphonate treatment. A potential CV benefit of bisphosphonates, beyond the impact on bones, could be considered.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries